Compare Amphastar Pharmaceuticals Inc (AMPH) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Ulta Beauty Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Ulta Beauty Inc trades at $542.13 (market cap $23.59B). The key difference: Ulta Beauty Inc is far larger — about 27.3× Amphastar Pharmaceuticals Inc's market cap, and Ulta Beauty Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | ULTA | |
|---|---|---|
Market Cap | $863.95M | $23.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $706.82 |
52-Week Low | $16.87 | $450.75 |
Enterprise Value | $1.26B | $25.67B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
ULTA stock trades at $565.15, up 4.89% in the last session, with a bullish technical outlook supported by moving averages and strong support at $547. The company reported Q1 2026 EPS of $7.74, beating estimates, but faces margin compression with net income margin declining to 10.63% in 2025. Recent news highlights the end of its Target partnership as a potential growth opportunity, per BofA analysis on July 29, 2026.
The stock offers upside to the consensus price target of $618.29, with 57% of analysts rating it a buy, but risks include competitive pressures and volatile cash flows, with net cash flow turning negative in 2025. Investors should weigh robust ROE of 47.45% against elevated P/B of 9.41 and RSI levels suggesting overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
